Leela Barham sets out some wider context to the latest blog from NICE on the cost-effectiveness threshold used by the agency and highlights the opportunity for stakeholders to build their case for ...

A Medicare-covered program that offers support and medical advice for caregivers of patients with dementia may bring more benefit than a costly Alzheimer's medication, research finds. UC San Francisco ...

PIKIRAN RAKYAT - Pernahkah merasa pusing melihat tumpukan data atau daftar pengeluaran yang berantakan di Microsoft Excel? Di era digital saat ini, kemampuan mengolah data bukan lagi sekadar nilai ...

Now more than ever, we need to listen to and respect one another’s views and values, whether on the floor of Congress or in individual health care decisions. As former members of Congress on different ...

As populations age and healthcare budgets tighten, a new valuation framework shows why the “price” of a healthy year of life depends on who gains it, and where policy choices may be quietly ...

This plot shows how the value of a QALY change as an individual gets older according to four different scenarios. Each scenario illustrate that a possible trajectory of an individual’s quality of life ...

This change, from April 2026, is designed to improve the operating environment for pharmaceutical companies in the UK to maximise the government’s commitment to unlock innovation and support the ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. The UK faces spending billions of pounds more on drugs bought by the NHS as the government proposes paying up ...

The National Institute for Health and Care Excellence (NICE), the body that determines the clinical effectiveness and economic value of new medicines, has increased the cost-effectiveness thresholds ...

ZOOM CALLS are rarely matters of life and death. But on April 3rd one such meeting carried grave consequences for 33 children in England with a form of Batten disease, a rare degenerative brain ...

Two popular medications used in the fight against obesity—semaglutide (Wegovy; Novo Nordisk) and tirzepatide (Zepbound; Eli Lilly)—are priced too high to be considered cost-effective by currently ...